{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:56:48Z","timestamp":1787871408432,"version":"build-2784847793"},"reference-count":155,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013500","name":"Canadian Cardiovascular Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.cjca.2013.09.023","type":"journal-article","created":{"date-parts":[[2013,9,29]],"date-time":"2013-09-29T04:36:07Z","timestamp":1380429367000},"page":"1553-1568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update"],"prefix":"10.1016","volume":"29","author":[{"given":"G.B. John","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Yashar","family":"Tashakkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fitchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Frohlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.09.023_bib1","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib2","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jamainternmed.2013.6184","article-title":"Statins and musculoskeletal conditions, arthropathies, and injuries","volume":"173","author":"Mansi","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.09.023_bib4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2013.09.023_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CND.0b013e3182852558","article-title":"Outcomes of statin myopathy after statin withdrawal","volume":"14","author":"Armour","year":"2013","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.cjca.2013.09.023_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/JRS-2012-0577","article-title":"Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis","volume":"24","author":"Savage","year":"2012","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.22081","article-title":"Transcriptional deficits in oxidative phosphorylation with statin myopathy","volume":"44","author":"Hubal","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2013.09.023_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.taap.2012.06.020","article-title":"Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signalling in healthy volunteers","volume":"263","author":"Galtier","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cjca.2013.09.023_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.taap.2012.01.008","article-title":"Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins","volume":"259","author":"Sirvent","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cjca.2013.09.023_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archinternmed.2011.1029","article-title":"Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis","volume":"172","author":"Garrison","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.21847","article-title":"Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications","volume":"43","author":"Wu","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2013.09.023_bib13","first-page":"177","article-title":"Diagnosis and management of patients with mitochondrial disease","volume":"53","author":"Mattman","year":"2001","journal-title":"BC Med J"},{"key":"10.1016\/j.cjca.2013.09.023_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jacl.2012.08.003","article-title":"Safety of statin therapy in patients with mitochondrial diseases","volume":"7","author":"Hannah-Shmouni","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib15","article-title":"Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease","volume":"2012","author":"Li","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cjca.2013.09.023_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.11.005","article-title":"Statins as a possible cause of inflammatory and necrotizing myopathies","volume":"222","author":"Padala","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2013.09.023_bib17","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2013.09.023_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cjca.2013.09.023_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2013.09.023_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-511X-11-40","article-title":"Statin therapy, myopathy and exercise\u2013a case report","volume":"11","author":"Semple","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.cjca.2013.09.023_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib23","first-page":"104","article-title":"A\u00a0randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design","volume":"13","author":"Thompson","year":"2010","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.09.023_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","article-title":"FDA drug safety communications: a narrative review and clinical considerations for older adults","volume":"10","author":"Marcum","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.cjca.2013.09.023_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinte.164.2.153","article-title":"Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry","volume":"164","author":"Golomb","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1345\/aph.1Q620","article-title":"Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations","volume":"46","author":"Rojas-Fernandez","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2013.09.023_bib30","doi-asserted-by":"crossref","unstructured":"Ott B, Daiello L, Springate B, et al. Do statin drugs impair cognition? A systematic review and meta-analysis. Alzheimers Dement 2013;9(Suppl):P666.","DOI":"10.1016\/j.jalz.2013.05.1372"},{"key":"10.1016\/j.cjca.2013.09.023_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/gps.3797","article-title":"Cochrane review on 'Statins for the treatment of dementia'","volume":"28","author":"McGuinness","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.cjca.2013.09.023_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/00207454.2013.778846","article-title":"Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs","volume":"123","author":"Pandey","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.cjca.2013.09.023_bib33","first-page":"446","article-title":"Neurological adverse drug reactions and statin therapy","volume":"4","author":"Abdulrazzaq","year":"2012","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archinternmed.2012.2171","article-title":"Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial","volume":"172","author":"Golomb","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.amjcard.2012.12.047","article-title":"Relation of statin therapy to psychological functioning in patients with an implantable cardioverter defibrillator","volume":"111","author":"Hoogwegt","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/phar.1272","article-title":"Psychologic disorders and statin use: a propensity score-matched analysis","volume":"33","author":"Mansi","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2013.09.023_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4088\/JCP.11m07038","article-title":"Statin use and risk of depression in patients with coronary heart disease; longitudinal data from the Heart and Soul Study","volume":"73","author":"Otte","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.cjca.2013.09.023_bib38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral haemorrhage: a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2013.09.023_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib41","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/STROKEAHA.112.657486","article-title":"Statin use and microbleeds in patients with spontaneous intracerebral haemorrhage","volume":"43","author":"Haussen","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2013.09.023_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.diabet.2010.09.005","article-title":"Statin therapy and cataract in type 2 diabetes","volume":"37","author":"Hermans","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cjca.2013.09.023_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/OPX.0b013e3182644cd1","article-title":"Age-related cataract is associated with type 2 diabetes and statin use","volume":"89","author":"Machan","year":"2012","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2011.08.001","article-title":"Recent statin use and cataract surgery","volume":"153","author":"Fong","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cjca.2013.09.023_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.cjca.2013.09.023_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2011.155622","article-title":"Use of statins is associated with an increased risk of rheumatoid arthritis","volume":"71","author":"de Jong","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2013.09.023_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/smj.2012.012004","article-title":"Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study","volume":"57","author":"Kumar","year":"2012","journal-title":"Scott Med J"},{"key":"10.1016\/j.cjca.2013.09.023_bib49","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/acr.22029","article-title":"The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study","volume":"65","author":"Myasoedova","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2013.09.023_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2013.09.023_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.30645","article-title":"Use of atorvastatin in systemic lupus erythematosus in children and adolescents","volume":"64","author":"Schanberg","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2013.09.023_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.semarthrit.2011.06.002","article-title":"Association between statin use and lupus-like syndrome using spontaneous reports","volume":"41","author":"de Jong","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cjca.2013.09.023_bib53","doi-asserted-by":"crossref","first-page":"e41289","DOI":"10.1371\/journal.pone.0041289","article-title":"Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case\/non-case approach","volume":"7","author":"de Jong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2013.09.023_bib54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/0961203312436861","article-title":"Statin-induced lupus: a case\/non-case study in a nationwide pharmacovigilance database","volume":"21","author":"Moulis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.cjca.2013.09.023_bib55","first-page":"743","article-title":"Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors","volume":"61","author":"Massay","year":"2012","journal-title":"West Indian Med J"},{"key":"10.1016\/j.cjca.2013.09.023_bib56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3346\/jkms.2012.27.3.268","article-title":"Spontaneously reported hepatic adverse drug events in Korea: multicenter study","volume":"27","author":"Kwon","year":"2012","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cjca.2013.09.023_bib58","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s10620-011-1950-1","article-title":"Jaundice due to suspected statin hepatotoxicity: a case series","volume":"57","author":"Bergmann","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib59","first-page":"92","article-title":"Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with \u03b1-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients","volume":"11","author":"Malaguarnera","year":"2011","journal-title":"Hepat Mon"},{"key":"10.1016\/j.cjca.2013.09.023_bib60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacl.2012.01.009","volume":"6","author":"Han","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2013.09.023_bib61","first-page":"374","article-title":"Why cardiac patients discontinued lipid lowering agents: views on gastrointestinal adverse reactions and their risk factors","volume":"4","author":"Abdulrazzaq","year":"2012","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib62","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.atherosclerosis.2011.12.011","article-title":"Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program","volume":"221","author":"Stein","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2013.09.023_bib63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","article-title":"Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FJC.0b013e318256cdf0","article-title":"Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects","volume":"60","author":"Morgan","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2013.09.023_bib66","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.09.023_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/clp.13.5","article-title":"Increased frequency of microalbuminuria in patients receiving statins","volume":"8","author":"Robles","year":"2013","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib68","doi-asserted-by":"crossref","first-page":"e31639","DOI":"10.1371\/journal.pone.0031639","article-title":"Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study","volume":"7","author":"van der Tol","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2013.09.023_bib69","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib70","first-page":"581","article-title":"Statin use and the risk of incident diabetes mellitus: a review of the literature","volume":"28","author":"Colbert","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib71","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjcard.2010.09.031","article-title":"Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation","volume":"107","author":"Thongtang","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib72","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1742-1241.2011.02779.x","article-title":"Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin\/ezetimibe on parameters of insulin resistance","volume":"65","author":"Moutzouri","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cjca.2013.09.023_bib73","doi-asserted-by":"crossref","first-page":"e17554","DOI":"10.1371\/journal.pone.0017554","article-title":"Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the randomized DIATOR Trial","volume":"6","author":"Martin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2013.09.023_bib74","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.09.023_bib75","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib76","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.09.023_bib77","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.clinthera.2012.08.004","article-title":"Statins and new-onset diabetes: a retrospective longitudinal cohort study","volume":"34","author":"Ma","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib78","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2012.05.019","article-title":"Statins, risk of diabetes, and implications on outcomes in the general population","volume":"60","author":"Wang","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/clpt.2011.83","article-title":"Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels","volume":"90","author":"Tatonetti","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/cts.12001","article-title":"The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations","volume":"5","author":"Burghardt","year":"2012","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cjca.2013.09.023_bib82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCOUTCOMES.111.000015","article-title":"Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins","volume":"6","author":"Ko","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2013.09.023_bib83","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib84","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib86","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11255-012-0126-z","article-title":"Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study","volume":"44","author":"Gokce","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.cjca.2013.09.023_bib88","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00228-012-1218-5","article-title":"Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature","volume":"68","author":"Roberto","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.09.023_bib89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1164\/rccm.201108-1574OC","article-title":"Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation","volume":"185","author":"Xu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib90","doi-asserted-by":"crossref","first-page":"e742","DOI":"10.3399\/bjgp11X606654","article-title":"Risk of pneumonia in patients taking statins: population-based nested case-control study","volume":"61","author":"Vinogradova","year":"2011","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.cjca.2013.09.023_bib91","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease","volume":"47","author":"Mancini","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib92","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jacc.2011.04.015","article-title":"Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans","volume":"58","author":"Marelli","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib93","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/1940-6207.CAPR-11-0113","article-title":"Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies","volume":"4","author":"Lee","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.cjca.2013.09.023_bib94","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/14740338.2012.712960","article-title":"Statin use and the risk of bladder cancer: a population-based case-control study","volume":"11","author":"Kuo","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2013.09.023_bib95","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/0008-5472.CAN-10-2953","article-title":"Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort","volume":"71","author":"Jacobs","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2013.09.023_bib96","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.111.081059","article-title":"Statins and the risk of cancer after heart transplantation","volume":"126","author":"Fr\u00f6hlich","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.09.023_bib97","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/bjc.2012.536","article-title":"Use of statins and risk of glioma: a nationwide case-control study in Denmark","volume":"108","author":"Gaist","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2013.09.023_bib98","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"31","author":"Tsan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2013.09.023_bib99","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10549-011-1858-7","article-title":"A\u00a0short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer","volume":"131","author":"Higgins","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cjca.2013.09.023_bib100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000346751","article-title":"Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy","volume":"90","author":"Kontraros","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.cjca.2013.09.023_bib101","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.12.11","article-title":"Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions","volume":"13","author":"Feng","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.09.023_bib102","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib103","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2710.2012.01337.x","article-title":"Genetic predisposition to atorvastatin-induced myopathy: a case report","volume":"37","author":"Francesca Notarangelo","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.cjca.2013.09.023_bib105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SCLO1B1 predispose to statin intolerance in routinely treated indivudals with type 2 diabetes: a Go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib106","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/FPC.0b013e3283557c98","article-title":"Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia","volume":"22","author":"Hu","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2013.09.023_bib107","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mus.22115","article-title":"Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS","volume":"44","author":"Isackson","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2013.09.023_bib108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","author":"Hoenig","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","article-title":"Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies","volume":"104","author":"Vladutiu","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2013.09.023_bib110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A\u00a0statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2013.09.023_bib111","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"Degorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2013.09.023_bib112","first-page":"146","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib113","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2169\/internalmedicine.50.4484","article-title":"Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration","volume":"50","author":"Oshima","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib114","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2013.09.023_bib115","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s12185-012-1226-3","article-title":"Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone","volume":"96","author":"Shahan","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cjca.2013.09.023_bib116","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11096-012-9717-0","article-title":"Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction","volume":"34","author":"Marusic","year":"2012","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.cjca.2013.09.023_bib117","doi-asserted-by":"crossref","first-page":"106","DOI":"10.12968\/hmed.2012.73.2.106","article-title":"Acute rhabdomyolysis caused by concurrent therapy with atorvastatin and warfarin","volume":"73","author":"Mackay","year":"2012","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.cjca.2013.09.023_bib118","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5144\/0256-4947.2012.309","article-title":"A\u00a0fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis","volume":"32","author":"Noordally","year":"2012","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib119","first-page":"38","article-title":"Interaction between simvastatin and cranberry juice in an elder","volume":"20","author":"Goldenberg","year":"2012","journal-title":"Clin Geriatr"},{"key":"10.1016\/j.cjca.2013.09.023_bib120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4066\/AMJ.2013.1616","article-title":"Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications","volume":"6","author":"Fallah","year":"2013","journal-title":"Australas Med J"},{"key":"10.1016\/j.cjca.2013.09.023_bib121","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-5491.2011.03502.x","article-title":"Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction","volume":"29","author":"Bhome","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib122","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/0975-3583.102720","article-title":"Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin","volume":"3","author":"Alreja","year":"2012","journal-title":"J\u00a0Cardiovasc Dis Res"},{"key":"10.1016\/j.cjca.2013.09.023_bib123","doi-asserted-by":"crossref","first-page":"88","DOI":"10.18773\/austprescr.2012.040","article-title":"Fatal rhabdomyolysis following voriconazole and simvastatin","volume":"35","author":"Doran","year":"2012","journal-title":"Aust Prescr"},{"key":"10.1016\/j.cjca.2013.09.023_bib124","first-page":"59","article-title":"Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone","volume":"5","author":"Elazzazy","year":"2012","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.cjca.2013.09.023_bib125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5694\/mja12.10333","article-title":"Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin","volume":"197","author":"Oh","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.cjca.2013.09.023_bib126","doi-asserted-by":"crossref","first-page":"e6562","DOI":"10.1136\/bmj.e6562","article-title":"Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid","volume":"345","author":"Kearney","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.09.023_bib127","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.revmed.2012.09.006","article-title":"Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid","volume":"34","author":"Gabignon","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.cjca.2013.09.023_bib128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7326\/0003-4819-158-12-201306180-00004","article-title":"Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study","volume":"158","author":"Patel","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjca.2013.09.023_bib131","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1185\/03007995.2011.648264","article-title":"Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin","volume":"28","author":"Yu","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2013.09.023_bib132","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacl.2011.05.005","article-title":"Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia","volume":"5","author":"Harris","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib133","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14740338.2012.630659","article-title":"Is there clinical benefit to routine enzyme testing of patients on statins?","volume":"11","author":"Elhayany","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2013.09.023_bib134","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF03256413","article-title":"Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy","volume":"15","author":"Skottheim","year":"2011","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.321115041","article-title":"Imaging features of therapeutic drug-induced musculoskeletal abnormalities","volume":"32","author":"Sidhu","year":"2012","journal-title":"Radiographics"},{"key":"10.1016\/j.cjca.2013.09.023_bib136","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/heartjnl-2012-302014","article-title":"Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK","volume":"98","author":"Collins","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2013.09.023_bib137","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib138","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1755-5922.2011.00267.x","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2013.09.023_bib139","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.09.023_bib140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.09.023_bib141","first-page":"915","article-title":"Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin","volume":"29","author":"Goldberg","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib142","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacl.2011.03.454","article-title":"Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance","volume":"5","author":"Kennedy","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib143","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1185\/03007995.2012.657302","article-title":"Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study","volume":"28","author":"Meek","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2013.09.023_bib144","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1185\/03007995.2011.598144","article-title":"Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance","volume":"27","author":"Glueck","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2013.09.023_bib145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2265.2011.04321.x","article-title":"Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins","volume":"77","author":"Kurnik","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cjca.2013.09.023_bib146","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1185\/03007995.2012.702102","article-title":"Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D","volume":"28","author":"Riphagen","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2013.09.023_bib147","first-page":"98","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","author":"Zlatohlavek","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.cjca.2013.09.023_bib148","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.cjca.2013.09.023_bib149","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.09.023_bib150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jacl.2011.09.004","article-title":"A\u00a0multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability)","volume":"6","author":"Karl","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2013.09.023_bib151","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in\u00a0high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.09.023_bib152","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.09.023_bib153","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.09.023_bib154","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2013.09.023_bib155","first-page":"151","article-title":"2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13014712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13014712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:11Z","timestamp":1760107091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X13014712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":155,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0828282X13014712"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.09.023","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2013.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}